Are you looking to uncover critical insights into your therapy’s mechanism of action? Struggling with translating preclinical results into clinical success? Bioleap is offering a fully funded, zero-cost pilot to help you de-risk your R&D with advanced mechanistic modeling.
Important Note:
1. This grant is issued by Bioleap and is not intended as a backdoor advertisement or solicitation.
2. Participation in the program is fully funded, and there is no cost to applicants. All data shared during the process will remain secure.
3. Please do not include any confidential information in your application.
📌 Your data stays yours - We do not claim IP. All insights generated will be shared confidentially
🔍 About Grant - Click here to read more about the grant and scope
⏳ Deadline - To be announced
e.g., Transcriptomics, Proteomics, Bioinformatics, PK/PD Data, QSP Models, Preclinical Animal Data, Patient-Derived Xenograft (PDX) Models, Single-Cell RNA Sequencing, Circulating Tumor DNA (ctDNA) Data, Immunophenotyping Data, Cytokine Profiles, Early Clinical Biomarker Data, Patient Stratification Data, Tumor Microenvironment Data, Organoid Models, CRISPR Screening Data, Single-Cell Multiomics Data, Spatial Transcriptomics, Metabolomics Data, Toxicology Data, In Vivo Imaging Data, Knockout/Knock-in Mouse Models, Functional Assays, Epigenetic Data, Other (Please Specify)
e.g., Hematological Malignancies (e.g., Lymphoma, Leukemia), Solid Tumors (e.g., Lung, Breast, Pancreatic, Ovarian...), Immuno-Oncology Targets, Other (Please Specify)
Please describe the key questions related to your data that you believe could benefit from Bioleap's ability to extract mechanistic insight (e.g. disease models, target validation, interpreting/validating pre-clinical data, sources of variability).
📩 Please submit your application via PDF or through the this online form.
✅ All applications will be reviewed based on their scientific feasibility and alignment with Bioleap's areas of expertise.
For more information, visit our
website or contact us directly at
[email protected].Jacob Halatek & Rohit Kumar-Makol, Founders
Bioleap, Salisbury House, Station Road, Cambridge, UK
